Others

Zydus receives approval from USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA

| Updated on June 04, 2016 Published on June 04, 2016

Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 04, 2016 titled "Zydus receives approval from USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA"

Pdf Link: >Zydus receives approval from USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA

Source : BSE - >www.bseindia.com

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on June 04, 2016
This article is closed for comments.
Please Email the Editor